Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Valneva SE - American Depositary Shares (NQ:VALN)

8.880 +0.040 (+0.45%)
Streaming Delayed Price Updated: 12:33 PM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Valneva SE - American Depositary Shares

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
From Pomerantz LLP
Via GlobeNewswire
VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
From Pomerantz LLP
Via GlobeNewswire
Novavax’s dispute resolution and upcoming earnings call
Novavax navigates legal settlements, earnings expectations, and competition, hoping their protein-based vaccines become a global health game-changer. 
Via MarketBeat
Topics Earnings
Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®
From VBI Vaccines Inc.
Via Business Wire
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
From Pfizer Inc.
Via Business Wire
Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15
From Pfizer Inc.
Via Business Wire
Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
From Pfizer Inc.
Via Business Wire
NASDAQ:VALN Shareholder Notice: Investigation Concerning Possible Wrongdoing at Valneva SE
San Diego, CA -- (SBWIRE) -- 11/08/2021 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Valneva SE. 
Via SBWire
NASDAQ:VALN Investor Notice: Investigation over Potential Securities Laws Violations by Valneva SE
San Diego, CA -- (SBWIRE) -- 09/27/2021 -- Valneva SE is under investigation over possible securities laws violations by in connection with certain financial statements. 
Via SBWire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.